Business Context and Reporting Period
Company: Aethlon Medical, Inc. (AEMD.OB)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Status: Development Stage Company; Smaller Reporting Company
Aethlon Medical is a development-stage medical device company focused on the Hemopurifier(R) platform, designed to remove viruses and toxins from human blood. The company has not generated significant revenue from principal operations and is seeking regulatory approval (FDA) to initiate clinical trials in the United States. The financial statements are prepared on a going concern basis, though significant doubt exists regarding the company's ability to continue operations without additional capital.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 | Three Months Ended June 30, 2007 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Expenses | $623,659 | $871,273 |
| Operating Loss | $(623,659) | $(871,273) |
| Net Loss | $(998,815) | $(536,199) |
| Loss Per Share (Basic & Diluted) | $(0.03) | $(0.02) |
| Cash and Cash Equivalents (End of Period) | $156,904 | $2,658 |
| Net Cash Used in Operating Activities | $(597,787) | $(433,451) |
| Total Current Liabilities | $4,034,341 | N/A |
| Working Capital | $(3,840,948) | N/A |
Debt Obligations (June 30, 2008):
- Notes Payable (Net): $863,087
- Convertible Notes Payable (Net): $353,241
- Due to Related Parties: $921,063
- Warrant Obligation: $445,403
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $462,616 (86%) compared to the prior year quarter, primarily driven by a $476,147 increase in interest and debt expenses.
- Interest Expense Surge: Interest expense rose from $86,701 to $562,848. This was largely due to the amortization of debt discounts ($463,178) and deferred financing costs ($38,250) associated with recent debt financings, which were not present in the prior year.
- Operating Expense Reduction: Total operating expenses decreased by $247,614 (28%). This reduction was primarily due to a $214,009 decrease in non-cash stock-based compensation within payroll expenses.
- Liquidity Position: Cash decreased by $97,787 during the quarter. While cash on hand increased significantly from the prior year's quarter-end ($2,658), the company faces a substantial negative working capital position of approximately $3.84 million.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Capital Needs
Management states that current financial resources are insufficient to fund operations for the fiscal year ending March 31, 2009. The company estimates a minimum burn rate of $186,000 per month to sustain operations. Future viability depends on securing additional capital through debt or equity financing. Subsequent to the quarter-end, the company raised $300,000 via convertible notes.
Risks and Contingencies
- Going Concern: The company has accumulated a deficit of over $33 million since inception and is in default on certain debt obligations.
- Debt Defaults: As of the filing date, $352,500 in promissory and convertible notes are past due. Additionally, holders of the Amended Series A Convertible Notes notified the company of a default on July 30, 2008, due to failure to register warrants and missed interest payments.
- Regulatory Hurdles: Commercialization is contingent upon FDA approval for clinical trials, which is not guaranteed and could take years.
- Unusual Items: The financial results include significant non-cash items, including a $187,692 gain from the change in fair value of warrant liability and substantial amortization of debt discounts.
Investor Verification Checklist
- Debt Default Status: Verify the current status of negotiations to cure the default on the Amended Series A Convertible Notes and the $352,500 in past-due notes.
- Cash Runway: Confirm the sufficiency of the $300,000 raised post-quarter-end against the stated $186,000 monthly burn rate.
- Equity Dilution: Review the impact of recent debt conversions (including $33,000 in December 10% Notes and subsequent conversions by executives) on share count and dilution.
- Registration Rights: Assess the risk of further liquidated damages accruals due to the failure to register warrants by the March 31, 2008 deadline.
- Related Party Transactions: Scrutinize the $921,063 owed to related parties and the recent conversions of accrued debt by the CEO and Chief Science Officer into common stock.